Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

G1 Therapeutics Inc (NQ: GTHX )

7.150 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about G1 Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
From G1 Therapeutics
Via GlobeNewswire
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
From G1 Therapeutics
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GVP, PETQ, GTHX on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?
G1 Therapeutics stock is up on Wednesday following news that Pharmacosmos Group is acquiring GTHX for $7.15 per share. 
Via InvestorPlace
Analyst Ratings For G1 Therapeutics
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)
From Brodsky & Smith LLC
Via GlobeNewswire
G1 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of G1 Therapeutics, Inc. - GTHX
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)
From Brodsky & Smith LLC
Via GlobeNewswire
G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
Dow Tumbles Over 200 Points; CVS Health Cuts Profit Forecast
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Jumps Over 3%; Upstart Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Nasdaq Jumps 250 Points; Disney Earnings Beat Estimates
Via Benzinga
Topics Earnings
Exposures Financial
GTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning! 
Via InvestorPlace
Pharmacosmos Group to Acquire G1 Therapeutics
From G1 Therapeutics; Pharmacosmos
Via GlobeNewswire
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
While there’s no denying that G1 Therapeutics stock is highly speculative, investors should still check under the hood. 
Via InvestorPlace
Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble
G1 Therapeutics stock is highly volatile, and investors should be wary now as G1 Therapeutics recently failed to achieve a clinical goal. 
Via InvestorPlace
Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears
A 2024 coffee recall is in effect for products made by Snapchill LLC due to concerns of botulism from the FDA for hundreds of canned coffees. 
Via InvestorPlace
Exposures Product Safety
Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts
Ginkgo Bioworks layoffs are a hot topic as the company prepares to cut 158 jobs this week with more headcount reductions coming next week. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
Alnylam Pharmaceuticals reports positive results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy. The trial showed significant reductions in mortality and... 
Via Benzinga
Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday?
Shares of G1 Therapeutics are down after release of Phase 3 trial results for trilaciclib in TNBC. 
Via Benzinga
Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?
G1 Therapeutics stock is down on Monday as GTHX investors react to the company's Phase 3 clinical trial of trilaciclib failing. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news on Monday morning! 
Via InvestorPlace
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
From G1 Therapeutics
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.